Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals

Lee, Charles E.; Neuland, Michael E.; Teaford, Harry G.; Villacis, B.F.; Dixon, Patricia; Valtier, Sandra; Yeh, Chi-Hwa; Fournier, Donald C.; Charlesworth, Ernest N.

doi:10.1016/0091-6749(92)90224-p

Cited by 48 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IL-1b augments the function of epidermal Langerhans cells participating in the induction of the cell-mediated immune response by taking up allergens or haptens and presenting them to B and T cells in the lymph nodes [37]. Although the role of IL-6 in ICD remains unclear, it is produced in the cutaneous response to allergen challenge [38].…”

Section: Discussionmentioning

confidence: 99%

Oral administration of glucosylceramide ameliorates inflammatory dry-skin condition in chronic oxazolone-induced irritant contact dermatitis in the mouse ear

Yeom

Kim

Lee

et al. 2012

Journal of Dermatological Science

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Oral administration of glucosylceramide ameliorates inflammatory dry-skin condition in chronic oxazolone-induced irritant contact dermatitis in the mouse ear

Yeom

Kim

Lee

et al. 2012

Journal of Dermatological Science

View full text Add to dashboard Cite

“…Elevated levels of IL-6 are present in the skin lesions of patients with mycosis fungoides [7] or psoriasis [8], and in the blood of joint synovial fluids of patients with rheumatoid arthritis [9,10]. It is released in the cutaneous response to allergen challenge in atopic subjects [11], and may be involved in graft-versus-host disease [12]. IL-6 is a systemic mediator of the acute-phase response and many of its activities are shared by IL-1 [13,14].…”

Section: Introductionmentioning

confidence: 99%

IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes

Watson¹,

Whittaker

Smith

et al. 1996

Clinical and Experimental Immunology

146

View full text Add to dashboard Cite

SUMMARYUsing a quantitative monolayer adhesion assay, the current report shows that treatment of human umbilical vein endothelial cells (HUVEC) with IL-6 increases their adhesiveness for blood lymphocytes, particularly CD4 cells, but not for polymorphonuclear cells and monocytes. This effect, which was most pronounced when using low concentrations of the cytokine (0 . 1-1 . 0 U/ml) and a short incubation period (4 h), was also apparent with microvascular endothelial cells and a hybrid endothelial cell line. Skin lesions from patients with mycosis fungoides contain high levels of IL-6, and blood lymphocytes from patients with this disorder also exhibited an enhanced adhesion to IL-6-treated HUVEC. The cytokine enhanced intercellular adhesion molecule-1 (ICAM-1) expression and induced the expression of vascular cell adhesion molecule-1 (VCAM-1) and E-selectin on endothelial cells. Antibody blocking studies demonstrated that the vascular adhesion molecules ICAM-1, VCAM-1 and E-selectin and the leucocyte integrin LFA-1 all contributed to lymphocyte binding to endothelium activated by IL-6. It is proposed that IL-6 may be involved in the recruitment of lymphocytes into non-lymphoid tissue.

show abstract

“…IL-6 production may occur in three distinct patterns: monophasic early release, biphasic release with early and late peaks or prolonged release [35], The subjects demonstrating a single peak of IL-6 are positive at the skin test but are not clinically sensitive when they are naturally exposed to the challenge antigen. Conversely, sub jects who demonstrate biphasic or prolonged IL-6 release are clinically sensitive to environmental exposures.…”

Section: Il-6 and Allergic Diseasesmentioning

confidence: 99%

lnterleukin-6 and the Skin

Paquet

Pierard²

1996

Int Arch Allergy Immunol

108

View full text Add to dashboard Cite

Interleukin-6 is a pleiotropic cytokine with numerous biological activities. It is produced by normal constituents of the skin, including epidermal cells, fibroblasts and dermal endothelial cells. It is also synthesized by inflammatory cells infiltrating the skin in various pathological conditions. We reviewed the presumed activities of interleukin-6 in normal skin and in some diseases with cutaneous involvement. The action of some drugs used in dermatology was also considered with regard to the modulation of the cytokine release. It is concluded that several important cellular lineages of the skin release interleukin-6. The cytokine appears to play a crucial role in the pathogenesis of both local and systemic inflammation, tumor development and autoimmune diseases.

show abstract

Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals

Cited by 48 publications

References 27 publications

Oral administration of glucosylceramide ameliorates inflammatory dry-skin condition in chronic oxazolone-induced irritant contact dermatitis in the mouse ear

Oral administration of glucosylceramide ameliorates inflammatory dry-skin condition in chronic oxazolone-induced irritant contact dermatitis in the mouse ear

IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes

lnterleukin-6 and the Skin

Contact Info

Product

Resources

About